5/10/2026

Janusmed sex and gender

Janusmed sex and gender – Venetoclax

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Venetoclax

Venetoclax

Class : A

Show all info

Print

Contact us

  1. Venclyxto (venetoclax). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-10-24, cited 2026-04-09]

  2. NIH National Cancer Institute. Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL). Cancer statistics [www]. [cited 2026-04-09].

  3. Catovsky D, Wade R, Else M. The clinical significance of patients' sex in chronic lymphocytic leukemia. Haematologica. 2014;99(6):1088-94.

  4. Tettero JM, Cloos J, Bullinger L. Acute myeloid leukemia: does sex matter?. Leukemia. 2024;38(11):2329-2331.

  5. Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials. J Clin Pharmacol. 2023;63(8):950-960.

  6. Vigna E, Bruzzese A, Martino EA, Corsonello A, Caserta S, Labanca C et al. Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. Eur J Haematol. 2026;116(2):160-168.

  7. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Venclyxto (venetoclax). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-10-24, cited 2026-04-09]
  2. NIH National Cancer Institute. Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL). Cancer statistics [www]. [cited 2026-04-09].
  3. Catovsky D, Wade R, Else M. The clinical significance of patients' sex in chronic lymphocytic leukemia. Haematologica. 2014;99(6):1088-94.
  4. Tettero JM, Cloos J, Bullinger L. Acute myeloid leukemia: does sex matter?. Leukemia. 2024;38(11):2329-2331.
  5. Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials. J Clin Pharmacol. 2023;63(8):950-960.
  6. Vigna E, Bruzzese A, Martino EA, Corsonello A, Caserta S, Labanca C et al. Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. Eur J Haematol. 2026;116(2):160-168.
  7. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]